FDA approves booster shots of Pfizer COVID-19 vaccine for elderly, high-risk Americans
Image Credit: Shortpedia
The US Food and Drug Administration authorized a booster dose of the Pfizer Inc and BioNTech COVID-19 vaccine for those aged 65 and older and some high-risk Americans, paving the way for a quick rollout of the shots. The booster dose is to be administered at least six months after completion of the second dose, and the authorization would include people most susceptible to severe disease and those in jobs that left them at risk, the FDA said.